PsyRx

Company Overview

Snapshot

Founded in October 2019 by Asher Holzer, Asher Holtzer, Itay Hecht, and Kobi Buxdorf, PsyRx operates with 1–10 employees. The company became public on TASE in November 2025 through a reverse merger.

Business overview

PsyRx is a pharmaceutical R&D company focused on developing biological API psilocybin and ibogaine to GMP standards using biological bioreactor technology. The company aims to be a leading producer of GMP-standard ibogaine and psilocybin for pharmaceutical, food supplement, and other product development. Additionally, PsyRx is developing a novel antidepressant drug combining ibogaine with existing approved antidepressants, targeting improved efficacy and reduced side effects for depression and addiction treatment. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In November 2025, PsyRx became public on the TASE through a reverse merger. This strategic move provides the company with access to public markets, potentially accelerating its drug development initiatives for psychedelic- and ibogaine-based pharmaceuticals and enhancing its visibility within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

When was PsyRx founded?

PsyRx was founded in October 2019.

What is PsyRx's primary focus in drug development?

PsyRx focuses on developing biological API psilocybin and ibogaine to GMP standards using biological bioreactor technology, aiming to produce these compounds for pharmaceutical, food supplement, and other product development.

What was a significant corporate milestone for PsyRx?

In November 2025, PsyRx became public on the TASE through a reverse merger with CannaboTech, providing access to public markets and potentially accelerating its drug development initiatives.

Who are the co-founders of PsyRx?

PsyRx was co-founded by Asher Holzer, Asher Holtzer, Itay Hecht, and Kobi Buxdorf.

What is PsyRx's strategy for treating depression?

PsyRx aims to develop a revolutionary antidepressant drug based on a combination of ibogaine and existing approved antidepressants, focusing on reducing side effects and improving efficacy by leveraging potential synergies between these compounds.